Statins and sepsis: multiple modifications at multiple levels

Marius Terblanche, Yaniv Almog, Robert S. Rosenson, Terry S. Smith, Daniel G. Hackam

Research output: Contribution to journalReview articlepeer-review

238 Scopus citations

Abstract

Sepsis, an infection-induced inflammatory syndrome, is a leading and increasing cause of mortality worldwide. Animal and human observational studies suggest statins may prevent the morbidity and mortality associated with the sepsis syndrome. In this Review, we describe the demonstrated mechanisms through which statins modulate the inflammatory response associated with sepsis. These mechanisms include effects on cell signalling with consequent changes at the transcriptional level, the induction of haem oxygenase, the direct alteration of leucocyte-endothelial cell interaction, and the reduced expression of MHC II. Since statins do not target individual inflammatory mediators, but possibly reduce the overall magnitude of the systemic response, this effect could prove an important distinguishing feature modulating the host response to septic insults. This work establishes the biological plausibility needed for future trials of statins in critical illness.

Original languageEnglish
Pages (from-to)358-368
Number of pages11
JournalThe Lancet Infectious Diseases
Volume7
Issue number5
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Dive into the research topics of 'Statins and sepsis: multiple modifications at multiple levels'. Together they form a unique fingerprint.

Cite this